Crossmark

Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations

Crossref DOI link: https://doi.org/10.1186/s12943-024-02035-6

Published Online: 2024-06-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kaneko, Syuzo https://orcid.org/0000-0003-4558-9800
Takasawa, Ken https://orcid.org/0000-0001-8699-0858
Asada, Ken https://orcid.org/0000-0003-0548-4449
Shiraishi, Kouya https://orcid.org/0000-0002-5821-7400
Ikawa, Noriko

Machino, Hidenori https://orcid.org/0000-0001-6843-7696
Shinkai, Norio https://orcid.org/0000-0001-7998-8493
Matsuda, Maiko

Masuda, Mari https://orcid.org/0000-0003-2311-8696
Adachi, Shungo

Takahashi, Satoshi

Kobayashi, Kazuma

Kouno, Nobuji

Bolatkan, Amina

Komatsu, Masaaki https://orcid.org/0000-0003-0421-8085
Yamada, Masayoshi https://orcid.org/0000-0003-3979-5560
Miyake, Mototaka https://orcid.org/0009-0003-6287-7932
Watanabe, Hirokazu https://orcid.org/0009-0007-2914-6651
Tateishi, Akiko

Mizuno, Takaaki https://orcid.org/0000-0003-4642-0345
Okubo, Yu

Mukai, Masami https://orcid.org/0000-0001-6315-6078
Yoshida, Tatsuya

Yoshida, Yukihiro

Horinouchi, Hidehito https://orcid.org/0000-0001-9090-801X
Watanabe, Shun-Ichi

Ohe, Yuichiro

Yatabe, Yasushi

Saloura, Vassiliki

Kohno, Takashi https://orcid.org/0000-0002-5371-706X
Hamamoto, Ryuji https://orcid.org/0000-0002-2632-1334
Funding

Funding for this research was provided by:

JSPS Grant-in-Aid for Scientific Research (JP21H03550)

The Takeda Science Foundation

The Princess Takamatsu Cancer Research Fund (19-25108)

AMED Innovative Cancer Medical Practice Research Project (JP22ck0106643, JP22ck0106643)

JST CREST (JPMJCR1689)

JSPS Grant-in-Aid for Scientific Research on Innovative Areas (JP18H04908)

JST AIP-PRISM (JPMJCR18Y4)

The MEXT subsidy for the Advanced Integrated Intelligence Platform
License Information

Text and Data Mining valid from 2024-06-11

Version of Record valid from 2024-06-11
More Information

Article History

Received: 21 August 2023

Accepted: 30 May 2024

First Online: 11 June 2024

Declarations

:

: All methods were performed in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study was approved by the institutional review board of the National Cancer Center Japan (2005–109, 2016–496, 2019–018). In addition, this study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. All authors have read and approved the final version of the manuscript.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below